Experiences in the use of multiple doses of convalescent plasma in critically ill patients with COVID‐19: An early phase 1 descriptive study

Abstract

AbstractBackgroundAt the beginning of the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) pandemic, transfusion of coronavirus disease 2019 (COVID‐19) convalescent plasma (CCP) emerged as a potential therapeutic strategy to help patients severely afflicted by COVID‐19. The efficacy of CCP has been controversial as it depends on many variables pertaining to the plasma donor and the patient with COVID‐19, for example, time of convalescence or symptoms onset. This feasibility and descriptive study aimed to assess the safety of multiple doses of CCP in mechanically ventilated, intubated patients with respiratory failure due to COVID‐19.MethodsA cohort of 30 patients all experiencing severe respiratory failure and undergoing invasive mechanical ventilation in an intensive care unit, received up to five doses of 300–600 mL of CCP on alternate days (0, 2, 4, 6, and 8) until extubation, futility, or death.ResultsNineteen patients received five doses, seven received four, and four received two or three doses. At 28‐day follow‐up mark, 57% of patients recovered and were sent home, and the long‐term mortality rate was 27%. Ten severe adverse events reported in the study were unrelated to CCP transfusion. Independent of the number of transfused doses, most patients had detectable levels of total and neutralizing antibodies in plasma.ConclusionThis study suggests that transfusion of multiple doses of CCP is safe. This strategy may represent a viable option for future studies, given the potential benefit of CCP transfusions during the early stages of infection in unvaccinated populations and in settings where monoclonal antibodies or antivirals are contraindicated or unavailable.